Clinical Trial Update: Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadotropic Hypogonadism

Drugs mentioned

• BGS649

Snippet

Sponsor: Mereo BioPharma | Conditions: Hypogonadotropic Hypogonadism | Phase 2 | Status: COMPLETED | Results posted: 2020-11-25